Drug Type Small molecule drug |
Synonyms Aminoethylsulfonic acid, Aminoethylsulfonic acid (JAN), Taurine (JP17/USP/INN) + [7] |
Target |
Action antagonists, modulators |
Mechanism GluN2B antagonists(Glutamate [NMDA] receptor subunit epsilon 2 antagonists), Amino acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC2H7NO3S |
InChIKeyXOAAWQZATWQOTB-UHFFFAOYSA-N |
CAS Registry107-35-7 |
Start Date04 Jan 2027 |
Sponsor / Collaborator |
Start Date30 Dec 2026 |
Sponsor / Collaborator |
Start Date01 Jun 2026 |
Sponsor / Collaborator |

| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Dietary Supplement | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| disorder of aging | Preclinical | United States | 22 Jun 2025 |
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 3 | - | Taurine supplementation | rtgtoybkst(ssiwkhuyrd) = gkiioawmiz ttxwwfdwmi (ochibwjjxm ) | Positive | 07 Aug 2022 | ||
(Placebo) | rtgtoybkst(ssiwkhuyrd) = egrxyjstdt ttxwwfdwmi (ochibwjjxm ) | ||||||
Phase 1/2 | 15 | (Taurine Intervention Group) | fwchymqnaf(zmjsnuqoec) = ueiqdcgbrg oqtyefciww (zrszqeeniw, 0.18) View more | - | 09 Jul 2018 | ||
(Taurine Intervention) | kppuigyemk = kcpnoswglr yrsnzhkskl (ieuwchlkjw, uinabqqjyi - nvfvsmhqlz) View more | ||||||
Phase 2 | 121 | czqppnqbox(dniqvsmboc): P-Value = 0.004 View more | Positive | 01 Dec 2016 | |||
Placebo |





